Distinct associations of sputum and oral microbiota with atopic, immunologic, and clinical features in mild asthma.
Microbiome
allergic
asthma
corticosteroids
cytokines
oral
sputum
type 2 inflammation
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
26
09
2019
revised:
06
02
2020
accepted:
02
03
2020
pubmed:
17
4
2020
medline:
16
3
2021
entrez:
17
4
2020
Statut:
ppublish
Résumé
Whether microbiome characteristics of induced sputum or oral samples demonstrate unique relationships to features of atopy or mild asthma in adults is unknown. We sought to determine sputum and oral microbiota relationships to clinical or immunologic features in mild atopic asthma and the impact on the microbiota of inhaled corticosteroid (ICS) treatment administered to ICS-naive subjects with asthma. Bacterial microbiota profiles were analyzed in induced sputum and oral wash samples from 32 subjects with mild atopic asthma before and after inhaled fluticasone treatment, 18 atopic subjects without asthma, and 16 nonatopic healthy subjects in a multicenter study (NCT01537133). Associations with clinical and immunologic features were examined, including markers of atopy, type 2 inflammation, immune cell populations, and cytokines. Sputum bacterial burden inversely associated with bronchial expression of type 2 (T2)-related genes. Differences in specific sputum microbiota also associated with T2-low asthma phenotype, a subgroup of whom displayed elevations in lung inflammatory mediators and reduced sputum bacterial diversity. Differences in specific oral microbiota were more reflective of atopic status. After ICS treatment of patients with asthma, the compositional structure of sputum microbiota showed greater deviation from baseline in ICS nonresponders than in ICS responders. Novel associations of sputum and oral microbiota to immunologic features were observed in this cohort of subjects with or without ICS-naive mild asthma. These findings confirm and extend our previous report of reduced bronchial bacterial burden and compositional complexity in subjects with T2-high asthma, with additional identification of a T2-low subgroup with a distinct microbiota-immunologic relationship.
Sections du résumé
BACKGROUND
Whether microbiome characteristics of induced sputum or oral samples demonstrate unique relationships to features of atopy or mild asthma in adults is unknown.
OBJECTIVE
We sought to determine sputum and oral microbiota relationships to clinical or immunologic features in mild atopic asthma and the impact on the microbiota of inhaled corticosteroid (ICS) treatment administered to ICS-naive subjects with asthma.
METHODS
Bacterial microbiota profiles were analyzed in induced sputum and oral wash samples from 32 subjects with mild atopic asthma before and after inhaled fluticasone treatment, 18 atopic subjects without asthma, and 16 nonatopic healthy subjects in a multicenter study (NCT01537133). Associations with clinical and immunologic features were examined, including markers of atopy, type 2 inflammation, immune cell populations, and cytokines.
RESULTS
Sputum bacterial burden inversely associated with bronchial expression of type 2 (T2)-related genes. Differences in specific sputum microbiota also associated with T2-low asthma phenotype, a subgroup of whom displayed elevations in lung inflammatory mediators and reduced sputum bacterial diversity. Differences in specific oral microbiota were more reflective of atopic status. After ICS treatment of patients with asthma, the compositional structure of sputum microbiota showed greater deviation from baseline in ICS nonresponders than in ICS responders.
CONCLUSIONS
Novel associations of sputum and oral microbiota to immunologic features were observed in this cohort of subjects with or without ICS-naive mild asthma. These findings confirm and extend our previous report of reduced bronchial bacterial burden and compositional complexity in subjects with T2-high asthma, with additional identification of a T2-low subgroup with a distinct microbiota-immunologic relationship.
Identifiants
pubmed: 32298699
pii: S0091-6749(20)30478-4
doi: 10.1016/j.jaci.2020.03.028
pmc: PMC7554083
mid: NIHMS1584219
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Biomarkers
0
Cytokines
0
Banques de données
ClinicalTrials.gov
['NCT01537133']
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1016-1026Subventions
Organisme : NHLBI NIH HHS
ID : U10 HL098107
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI007334
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI129958
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002366
Pays : United States
Organisme : NHLBI NIH HHS
ID : R03 HL138310
Pays : United States
Informations de copyright
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Références
Sci Rep. 2017 Sep 11;7(1):11155
pubmed: 28894184
J Allergy Clin Immunol. 2013 Feb;131(2):346-52.e1-3
pubmed: 23265859
Am J Respir Crit Care Med. 2013 Nov 15;188(10):1193-201
pubmed: 24024497
J Allergy Clin Immunol. 2019 Nov;144(5):1187-1197
pubmed: 31201890
Curr Allergy Asthma Rep. 2016 Jul;16(8):52
pubmed: 27393699
Allergy. 2018 Oct;73(10):2000-2011
pubmed: 29602225
J Allergy Clin Immunol. 2018 Jan;141(1):257-268.e6
pubmed: 28433687
PLoS One. 2017 Oct 20;12(10):e0184566
pubmed: 29053714
J Asthma. 2017 Nov;54(9):893-904
pubmed: 28635548
PLoS One. 2010 Jan 05;5(1):e8578
pubmed: 20052417
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15858-63
pubmed: 17898169
J Allergy Clin Immunol. 2015 Oct;136(4):874-84
pubmed: 26220531
J Allergy Clin Immunol. 2017 Aug;140(2):407-417.e11
pubmed: 28042058
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
J Allergy Clin Immunol. 2016 May;137(5):1398-1405.e3
pubmed: 26627545
Microbiome. 2018 Jun 9;6(1):104
pubmed: 29885665
Am J Respir Crit Care Med. 2016 Jun 1;193(11):1281-91
pubmed: 26649486
Genet Mol Biol. 2013 Dec;36(4):475-85
pubmed: 24385847
mBio. 2017 Feb 14;8(1):
pubmed: 28196961
J Immunol. 2009 Feb 1;182(3):1404-10
pubmed: 19155487
Am J Respir Crit Care Med. 2009 Sep 1;180(5):388-95
pubmed: 19483109
Bioinformatics. 2010 Oct 1;26(19):2460-1
pubmed: 20709691
J Allergy Clin Immunol. 2018 Jan;141(1):82-83
pubmed: 28627361
Nat Commun. 2019 Dec 16;10(1):5714
pubmed: 31844063
Sci Transl Med. 2019 Aug 28;11(507):
pubmed: 31462509
J Allergy Clin Immunol. 2018 Jan;141(1):94-103.e15
pubmed: 28479329
PLoS One. 2016 Apr 14;11(4):e0152724
pubmed: 27078029
J Allergy Clin Immunol. 2019 Feb;143(2):577-590
pubmed: 29902480
Clin Transl Allergy. 2013 Jul 17;3(1):24
pubmed: 23866775
Eur Respir J. 2016 Mar;47(3):792-800
pubmed: 26647445
Lancet. 2018 Jan 27;391(10118):350-400
pubmed: 28911920
J Allergy Clin Immunol. 2017 Jul;140(1):63-75
pubmed: 27838347
J Allergy Clin Immunol. 2011 Feb;127(2):372-381.e1-3
pubmed: 21194740
BMC Pulm Med. 2016 Apr 05;16:46
pubmed: 27044366
Immunity. 2015 Aug 18;43(2):318-30
pubmed: 26287681
PLoS One. 2014 Jun 23;9(6):e100645
pubmed: 24955983
J Allergy Clin Immunol. 2019 Nov;144(5):1214-1227.e7
pubmed: 31279011